Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT1FS0
|
|||
| Drug Name |
AB154
|
|||
| Synonyms |
Domvanalimab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 3 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [2] | ||
| Company |
Arcus Biosciences; Gilead Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | V-set and immunoglobulin domain-containing protein 9 (TIGIT) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04736173) Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03628677) A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Arcus Biosciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.